Eight hospitals in Australia will conduct a 4-year trial of a vaccine for children with malignant brain cancer, involving approximately 70 young patients.
mRNA cancer vaccines have the potential to create up to 75 billion USD in value annually in the US alone, by increasing treatment efficacy and preventing cancer deaths.
